Pacira ((PCRX)) announced an update on their ongoing clinical study.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Pacira Pharmaceuticals is conducting a Phase 2 clinical study titled ‘A Phase 2, Randomized, Open-Label, Two-Arm Study to Evaluate a Procedure for Intra-Articular Injection of ZILRETTA Versus Triamcinolone Acetonide, Immediate Release (TCA-IR) in Subjects With Osteoarthritis of the Hip.’ The study aims to assess the effectiveness of an injection procedure using two different needle sizes in patients with hip osteoarthritis, highlighting its potential significance in improving treatment outcomes.
The study tests two interventions: ZILRETTA, an extended-release injectable suspension, and Triamcinolone Acetonide, an immediate-release formulation. Both are designed to alleviate symptoms of osteoarthritis in the hip.
This interventional study is randomized with a parallel assignment model, where participants are divided into two groups receiving either ZILRETTA or TCA-IR, with further subdivision based on needle gauge. The study is open-label, meaning no masking is involved, and its primary purpose is treatment.
The study began on May 7, 2025, with primary completion expected in the future. The latest update was submitted on September 10, 2025, indicating ongoing recruitment and study progress.
This study update could influence Pacira’s stock performance, as positive results may enhance investor confidence and market position, especially in comparison to competitors in the osteoarthritis treatment space.
The study is currently recruiting, with further details available on the ClinicalTrials portal.